Pulmonology Medical News about lung adenocarcinomas

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Modern Pathology, 10/28/09

Dacic S et al. – The cost–effectiveness of lung carcinoma mutational testing would be improved by initial determination of KRAS mutational status as negative predictor of the patient's response to EGFR tyrosine kinase inhibitors, followed by EGFR mutational analysis, if necessary.

<< Previous
Leukotriene E4-induced pulmonary inflammation is mediated by the...

Next >>
In utero Smoke Exposure and Maternal and Infant GST Genes on...

Diagnostic Efficacy of PET/CT Plus Brain MR Imaging for Detection of Extrathoracic Metastases in Patients with Lung Adenocarcinoma
Journal of Korean Medical Science, 11/16/09 Relevance Score: 69%

Use of EGFR/KRAS Mutation Testing To Define Clonal Relationships Among Multiple Lung Adenocarcinomas
Chest, 10/08/09 Relevance Score: 69%

Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas
Lung Cancer, 11/06/09 Relevance Score: 68%

Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Cancer Research, 11/02/09 Relevance Score: 68%

An Embryonic Stem Cell–Like Signature Identifies Poorly Differentiated Lung Adenocarcinoma but not Squamous Cell Carcinoma
Clinical Cancer Research, 10/12/09 Relevance Score: 68%